Abstract
Nature 466 (suppl.), S15–S18 (26 August 2010) This Outlook article stated that Addex Pharmaceuticals has mGluR5 modulators in phase II trials for anxiety and depression. The company says that its only disclosed mGluR5 inhibitor in development, ADX48621, will soon enter phase II testing for Parkinson’s disease levodopa-induced dyskinesia and non-Parkinson’s dystonia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
